Abstracts tagged "joint damage"

Abstract Number: 119 • 2015 ACR/ARHP Annual Meeting
Triage in Chronic Rheumatic Diseases: Quantitative Physician Estimates for Inflammation (Reversible), Damage (Irreversible), and Distress in Patients with Rheumatoid Arthritis, Osteoarthritis, and Fibromyalgia Seen in Usual Care
Isabel Castrejón¹, Kathryn A. Gibson², Ruchi Jain¹, Annie Huang¹, Joel A. Block³ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Liverpool Hospital, Liverpool, Australia, ³Rush University Medical Center, Chicago, IL
Background/Purpose: A physician estimate of a patient’s global status (DOCGL) often is most often the most efficient of all 7 rheumatoid arthritis (RA) core data…
Abstract Number: 135 • 2015 ACR/ARHP Annual Meeting
Limitations of Treat-to-Target in Rheumatoid Arthritis: Joint Damage Appears As Severe As Inflammation in Contemporary Care at One Site
Theodore Pincus¹, Alex D. Luta², Isabel Castrejón¹, Annie Huang¹, Ruchi Jain¹, Sarah L. Everakes³ and Joel A. Block⁴, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Georgetown University, Washington, DC, ³Internal Medicine, Rush University Medical Center, Chicago, IL, ⁴Rush University Medical Center, Chicago, IL
Background/Purpose: Treatment of rheumatoid arthritis is directed to “treat-to-target,” with intensification of therapy in patients with moderate/high disease activity according to a quantitative index toward…
Abstract Number: 509 • 2015 ACR/ARHP Annual Meeting
In Early Undifferentiated Polyarthritis, 14-3-3η Seroreversion or Sustained Negativity Is Associated with Better Radiographic Outcomes, Even in DAS-28 Remitters
Gilles Boire^1,2, Nathalie Carrier³, Artur de Brum-Fernandes^1,4, Patrick Liang^1,4, Ariel Masetto^2,5, Yuan Gui⁶, Jane Savill⁶, Sara Michienzi⁶, Henri Ménard⁷, Walter Maksymowych⁸ and Anthony Marotta⁶, ¹Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ²Department of Medicine/Division of Rheumatology, University of Sherbrooke, Sherbrooke, QC, Canada, ³Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ⁶Augurex Life Sciences Corp., Vancouver, BC, Canada, ⁷MSK Research Axis, McGill University Health Center Research Institute, Montreal, QC, Canada, ⁸Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Advancements in RA treatment approaches with DMARDs and biological agents have enabled disease remission goals that were previously considered unattainable. The concept of "tight…
Abstract Number: 513 • 2015 ACR/ARHP Annual Meeting
Cumulative Association of Genetic Variants with Rheumatoid Joint Damage Progression in Mexican Americans and European Americans
Rector Arya¹, Inmaculada del Rincon², Jose Felix Restrepo³, Vidya S Farook⁴, Christopher P Jenkinson⁵, Ravindranath Duggirala⁶ and Agustin Escalante⁷, ¹Pediatrics, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, ³Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ⁴Genetics, Texas Biomedical Research Institute, San Antonio, TX, ⁵University of Texas Health Science Center at San Antonio, San Antonio, TX, ⁶Regional Academic Health Center, Harlingen, TX, ⁷Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: Genealogical and genetic association studies have suggested that joint damage in rheumatoid arthritis (RA) may be heritable. We and others have found a number…
Abstract Number: 977 • 2015 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Active- and Placebo-Controlled Phase 3 Study of Efficacy and Safety of Ixekizumab, Adalimumab, and Placebo Therapy in Patients Naïve to Biologic Disease Modifying Anti-Rheumatic Drugs with Active Psoriatic Arthritis
Philip J. Mease¹, Désirée van der Heijde², Christopher T. Ritchlin³, Raquel Cuchacovich^4,5, Catherine L. Shuler⁵, Chin H. Lee⁵, Suvajit Samanta⁵, Chen-Yen Lin⁵, Dafna D. Gladman⁶ and Harald Vangerow⁵, ¹Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA, ²Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands, ³Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁴School of Medicine, Rheumatology Division, Indiana University, Indianapolis, IN, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease associated with psoriasis which includes peripheral arthritis, enthesitis, dactylitis, and spondylitis manifestations. Ixekizumab, under investigation…
Abstract Number: 1305 • 2015 ACR/ARHP Annual Meeting
Prevalence of MR-Detected Ramris-Defined Erosions in the General Population
L. Mangnus¹, H.W. van Steenbergen², M. Reijnierse³ and A.H.M. van der Helm- van Mil¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Radiology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The diagnostic value of Magnetic Resonance (MR) imaging for Rheumatoid Arthritis (RA) is undetermined. The main value of MR is its sensitive depiction of…
Abstract Number: 1307 • 2015 ACR/ARHP Annual Meeting
Does Computerized Segmentation of Early Erosions on Magnetic Resonance Imaging Predict Functional Ability in Rheumatoid Arthritis?
Matthew Jessome¹, Michael Tomizza¹, Karen A. Beattie², William G. Bensen², Raja Bobba², Alfred Cividino², Patrick D. Emond², Chris Gordon², Lawrence Hart², George Ioannidis², Maggie Larche², Arthur Lau³, Ruben Tavares², Stephen Tytus² and Jonathan D. Adachi², ¹McMaster University, Hamilton, ON, Canada, ²St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ³Division of Rheumatology, McMaster University, Hamilton, ON, Canada
Background/Purpose: Functional ability of rheumatoid arthritis (RA) patients is reduced by both acute (inflammatory) and chronic (joint damage) disease manifestations. However, the impact of early…
Abstract Number: 1325 • 2015 ACR/ARHP Annual Meeting
Age Effects Joint Space Narrowing in Early Active Rheumatoid Arthritis Patients
Xanthe M.E. Matthijssen¹, Gülsah Akdemir¹, Iris M. Markusse², Yvonne P. Goekoop-Ruiterman³, K. Huub Han⁴, Annekoos L. Huidekoper⁵, Pit J.S.M. Kerstens⁶, Willem F. Lems⁷, T. W. J. Huizinga¹ and Cornelia F. Allaart¹, ¹Rheumatology, LUMC, Leiden, Netherlands, ²LUMC, Leiden, Netherlands, ³Rheumatology, HAGA hospital, The Hague, Netherlands, ⁴Rheumatology, Maasstad hospital, Rotterdam, Netherlands, ⁵Rheumatology, Bronovo hospital, The Hague, Netherlands, ⁶Department of Rheumatology, Reade, Amsterdam, Netherlands, ⁷Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands
Background/Purpose: Joint space narrowing (JSN) and erosions are the major radiologic markers of radiographic progression in rheumatoid arthritis (RA), as scored by the Sharp/van der…
Abstract Number: 1716 • 2015 ACR/ARHP Annual Meeting
Prevalence of Joint Symptoms and Frequency of Joint Exams for Patients with Plaque Psoriasis without Confirmed Psoriatic Arthritis: A US Analysis
Tatiana Makhinova¹, Robert Wood², Derek Tang³, James Piercy², Steve Lobosco⁴, Bradley S. Stolshek⁵ and David J. Harrison⁵, ¹College of Pharmacy, University of Texas at Austin, Austin, TX, ²Adelphi Real World, Macclesfield, United Kingdom, ³Amgen, Inc., Thousand Oaks, CA, ⁴Adelphi Real World Ltd., Macclesfield, United Kingdom, ⁵Amgen Inc., Thousand Oaks, CA
Background/Purpose: Due to the high prevalence of PsA among patients with PsO,1 rheumatologists and dermatologists should recognize early signs and symptoms of joint involvement among…
Abstract Number: 1368 • 2014 ACR/ARHP Annual Meeting
Are Tender Joints Better Than Synovitis to Predict Structural Damage in Rheumatoid Arthritis?
Peter Cheung¹, Karine Mari², Valerie Devauchelle³, Jacques Bentin⁴, Sandrine Jousse-Joulin⁵, Maria-Antonietta d'Agostino⁶, Gérard Chales⁷, Isabelle Chary-Valckenaere⁸, Fabien Etchepare⁹, Philippe Gaudin¹⁰, Xavier Mariette¹¹, Alain Saraux¹² and Maxime Dougados¹³, ¹Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ²RCT, Lyon, France, ³Rheumatology, Brest university medical school, EA 2216, Lab Ex, INSERM, IGO,UBO and CHU de la Cavale Blanche,, Brest, France, ⁴Rheumatology, CHU-Brugmann, Brussels, Belgium, ⁵Rheumatology, CHU Brest, Brest, France, ⁶Rheumatology, Versailles-Saint Quentin en Yvelines University, Boulogne-Billancourt, France, ⁷Dept of Rheumatology, CHR - Hopital Sud, Rennes, France, ⁸Rheumatology, Nancy University Hospital, Nancy, France, ⁹AP-HP, La Pitié-Salpétrière Hospital, Rheumatology Department, Paris-VI University, Paris, France, ¹⁰Rhumatologie, Hopital Sud Grenoble, Echirolles, France, ¹¹Paris-Sud University, Paris, France, ¹²Rhumatologie, CHU Brest and EA 2216, UBO, Brest, France, ¹³Université Paris René Descartes and Hôpital Cochin, Paris, France
Background/Purpose: Longitudinal studies indicate that synovitis can predict subsequent structural damage in rheumatoid arthritis (RA) but the clinical relevance of tenderness is unclear. The aim…
Abstract Number: 1172 • 2014 ACR/ARHP Annual Meeting
Assessing the Validity and Reliability of a Novel MRI Semi-Automated Algorithm for Quantifying Bone Loss in the Hand
Matthew Jessome¹, Isabel Rodrigues², Michael Tomizza², Joshua Barbosa², Melissa XP. Koh¹, Karen Beattie³, William G. Bensen³, Raja Bobba³, Alfred Cividino³, Patrick D. Emond³, Karen Finlay⁴, Chris Gordon³, Lawrence Hart³, George Ioannidis³, Erik Jurriaans⁴, Maggie Larche³, Arthur Lau³, Naveen Parasu⁴, Ruben Tavares³, Stephen Tytus³, Hao Wu² and Jonathan D. Adachi^2,3, ¹Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁴Radiology, Hamilton Health Sciences, Hamilton, ON, Canada
Background/Purpose Efficient and accurate evaluation of erosive damage to the MCP joints in RA patients is desirable in both clinical trials and clinical practice. The…
Abstract Number: 1050 • 2014 ACR/ARHP Annual Meeting
A Role for Purinergic Receptor Signalling in Basic Calcium Phosphate Crystal-Induced Inflammation
Clare C. Cunningham¹, Emma M. Corr¹, Geraldine M. McCarthy² and Aisling Dunne¹, ¹School of Biochemistry and Immunology, Trinity College Dublin, Dublin 2, Ireland, ²Medicine/Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland
Background/Purpose: Basic calcium phosphate (BCP) crystals are uniquely associated with osteoarthritis (OA). They are found in the majority of affected joints and closely correlate with…
Abstract Number: 1005 • 2014 ACR/ARHP Annual Meeting
Histone Lysine Demethylase KDM6A Mediates Joint Destruction in Osteoarthritic Knees By Epigenetic Disturbance of SOX9 Promoter and Histone H3K27
Feng-Sheng Wang¹, Pe-Chin Chuang¹, Yi-Chih Sun¹, Yu-Shan Chen¹ and Jih-Yang Ko², ¹Department of Medical Research, Kaohsiung Chang Gung Memorial Hospital, Taiwan, Kaohsiung, Taiwan, ²Department of Orthopedic Surgery, Kaohsiung Chang Gung Memorial Hospital, Taiwan, Kaohsiung, Taiwan
Background/Purpose: Intensive articular cartilage deterioration and synovial fibrosis in joints are prominently pathogenic features of osteoarthritic (OA) knees. Epigenetic reactions in joint microenvironments are linked…
Abstract Number: 954 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Monoclonal Antibody to Interleukin-17A, Provides Significant and Sustained Inhibition of Joint Structural Damage in Active Psoriatic Arthritis Regardless of Prior TNF Inhibitors or Concomitant Methotrexate: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
Désirée van der Heijde¹, Robert B. M. Landewé², Philip J. Mease³, Iain B. McInnes⁴, Philip G. Conaghan⁵, Luminita Pricop⁶, Gregory Ligozio⁷, Hanno Richards⁸ and Shephard Mpofu⁹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, ³Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁴Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁵NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁶Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharma AG, Basel, Switzerland
Background/Purpose Approximately two-thirds of patients (pts) with psoriatic arthritis (PsA) experience progressive joint damage associated with varying degrees of disability. Here we present the 1-year…
Abstract Number: 137 • 2014 ACR/ARHP Annual Meeting
Evaluation of Metalloproteinase-3 As a Soluble Biomarker of Synovitis Using Weighted Joint Counts Assessed Clinically and on Ultrasound Imaging
Agata Burska^1,2, Elizabeth Hensor^2,3, Jackie L. Nam³, Lukasz Kozera⁴, Richard J. Wakefield³, Paul Emery³ and Ann W Morgan⁵, ¹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds., Leeds, United Kingdom, ²joint first authorship, Leeds, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Faculty of Pharmacy and Laboratory Diagnostics, Wroclaw Medical University, Wroclaw, Poland, Wroclaw, Poland, ⁵NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom
Background/Purpose: Synovial inflammation is known to play a central role in articular cartilage degradation in rheumatoid arthritis (RA); it could be a passive marker of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].